| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S2352-3026(14)70008-0 |
| P698 | PubMed publication ID | 27030064 |
| P50 | author | Luca Guerra | Q38803434 |
| Stefano Luminari | Q56826847 | ||
| Irene Biasoli | Q57013059 | ||
| Massimo Federico | Q57031724 | ||
| Corinne Haioun | Q59200159 | ||
| Judith Trotman | Q71716587 | ||
| P2093 | author name string | Gilles Salles | |
| Hervé Tilly | |||
| Jehan Dupuis | |||
| Luigi Marcheselli | |||
| Sami Boussetta | |||
| Annibale Versari | |||
| Anne Julian | |||
| Michel Meignan | |||
| Alina Berriolo-Riedinger | |||
| Antonella Franceschetto | |||
| Fabien Ricard | |||
| Christelle Tychyj | |||
| P2860 | cites work | Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group | Q33773306 |
| Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. | Q34156097 | ||
| Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification | Q34663865 | ||
| Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma | Q36715057 | ||
| Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience | Q37083964 | ||
| Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. | Q37240835 | ||
| Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and G | Q38056487 | ||
| End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis | Q38139833 | ||
| PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study | Q38179303 | ||
| Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants | Q39730021 | ||
| Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm? | Q43666600 | ||
| The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). | Q44592953 | ||
| Revised response criteria for malignant lymphoma | Q47582438 | ||
| Improved survival of follicular lymphoma patients in the United States. | Q50764033 | ||
| Report on the First International Workshop on Interim-PET-Scan in Lymphoma. | Q53058012 | ||
| Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. | Q53189779 | ||
| Follicular lymphoma international prognostic index. | Q53289840 | ||
| R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi | Q86491341 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | follicular lymphoma | Q123251 |
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | e17-27 | |
| P577 | publication date | 2014-09-17 | |
| P1433 | published in | The Lancet. Haematology. | Q26840042 |
| P1476 | title | Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies | |
| P478 | volume | 1 |
| Q47808320 | 18F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality? |
| Q37672472 | A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies |
| Q38394272 | Biosimilar monoclonal antibodies in lymphoma: a critical appraisal |
| Q64115851 | CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products |
| Q60019713 | Current challenges in the management of follicular lymphoma |
| Q90916353 | Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? - Authors' reply |
| Q37035820 | Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. |
| Q40533698 | Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. |
| Q90356373 | Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial |
| Q38836081 | FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas |
| Q35080079 | FDG PET-CT in follicular lymphoma: a case-based evidence review |
| Q38312367 | FDG PET/CT imaging as a biomarker in lymphoma. |
| Q33642244 | FDG-PET Scan: a new Paradigm for Follicular Lymphoma Management |
| Q52982144 | FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. |
| Q88801099 | Follicular Lymphoma: Past, Present, and Future |
| Q92185611 | Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs |
| Q92348038 | Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade |
| Q48540269 | Follicular lymphoma: are we ready for a risk-adapted approach? |
| Q26801870 | Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography |
| Q41008736 | Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy. |
| Q58606498 | Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment |
| Q89933141 | Non-Hodgkin lymphoma |
| Q52981841 | Overestimated value of FDG-PET based bone marrow evaluation in lymphoma: Response to Adams and Kwee. |
| Q26752284 | PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas |
| Q89090599 | PET-CT restaging: a surrogate for follicular lymphoma? |
| Q97645211 | Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma |
| Q42427611 | Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi |
| Q30240241 | Prognostic factors in follicular lymphoma: new tools to personalize risk |
| Q57481825 | Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial |
| Q64086572 | Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma |
| Q49027912 | Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19-20 September 2014. |
| Q33574197 | Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. |
| Q90029115 | Sequencing of therapies in relapsed follicular lymphoma |
| Q28073262 | Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How |
| Q91786165 | The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice |
| Q33565265 | The clinical development of obinutuzumab for the treatment of follicular lymphoma |
| Q104567531 | The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma |
| Q92898102 | Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden |
| Q47771789 | Transformed follicular lymphoma. |
| Q50710717 | Unmet needs in the first-line treatment of follicular lymphoma. |
| Q38523981 | VI. FDG-PET as a biomarker in lymphoma: from qualitative to quantitative analysis |
| Q46450889 | [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice |
Search more.